Literature DB >> 9249066

Leukemia breakpoint region in 3q21 is gene rich.

A Rynditch1, Y Pekarsky, S Schnittger, K Gardiner.   

Abstract

Rearrangements of the long arm of human chromosome 3, including reciprocal translocations, inversions and deletion/duplication of bands 3q21-3q26, as well as deletions of 3q21 and reciprocal translocations between 3q21 and other chromosomes, are well documented in leukemia. Previous studies showed that the breakpoints within 3q21 cluster within a 10-40 kb region but no candidate genes were described. In this work, we have identified partial cDNAs corresponding to five to nine new transcripts from an 80 kb P1 clone that spans ten breakpoints. These transcripts, with one exception, appear to be expressed only at low levels in the set of cancer cell lines examined. Four transcripts are located between the previously mapped Ribophorin I gene and the most centromeric breakpoint; three map directly within the 20 kb spanning nine independent breakpoints. These data (i) show that among characterized leukemia breakpoint regions 3q21 is unusually gene rich, (ii) provide new candidates for relevance to leukemia in 3q21, and (iii) suggest possibilities for chromatin configuration effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249066     DOI: 10.1016/s0378-1119(97)00076-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  TIP49b, a regulator of activating transcription factor 2 response to stress and DNA damage.

Authors:  S G Cho; A Bhoumik; L Broday; V Ivanov; B Rosenstein; Z Ronai
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 2.  The roles of SNF2/SWI2 nucleosome remodeling enzymes in blood cell differentiation and leukemia.

Authors:  Punit Prasad; Andreas Lennartsson; Karl Ekwall
Journal:  Biomed Res Int       Date:  2015-02-19       Impact factor: 3.411

3.  A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Authors:  Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Zahra Kmeira; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.